<DOC>
	<DOCNO>NCT00423020</DOCNO>
	<brief_summary>The EPOC-AMI study ass safety efficacy systemic administration erythropoietin inhibition neointimal hyperplasia stent implantation patient acute myocardial infarction</brief_summary>
	<brief_title>Anti-Restenosis After AMI Erythropoietin</brief_title>
	<detailed_description>Stents coat sirolimus paclitaxel show significantly reduce restenosis select coronary lesion . However , potential risk late stent thrombosis force prolong treatment dual anti-platelet regimen patient implantation drug elute stent . Patients acute myocardial infarction may uncertain clinical characteristic , occult bleeding focus need surgical procedure . Thus , bare metal stent considerably alternative primary PCI AMI remain appreciable number patient risk restenosis . Use systemic pharmacological therapy inhibit coronary stent restenosis bare metal stent largely unsuccessful . We report erythropoietin could enhance reendothelialization lead inhibition in-stent restenosis directly protect endothelial apoptosis mobilize endothelial progenitor . The EPOC-AMI study design assess safety efficacy systemic administration erythropoietin aim inhibition neointimal hyperplasia stent implantation patient acute myocardial infarction .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Clinical diagnosis acute myocardial infarction within 12hrs symptom onset . Succeeded reperfusion due primary PCI accomplish bare metal stent Patients cardiogenic shock ( e.g . systolic BP &lt; 80mmHg , use catecholamine , use IABP ) Patients anemia require transfusion Patients unwilling unable comply trial protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Restenosis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPOC-AMI</keyword>
</DOC>